{"id":1690,"date":"2025-07-10T13:08:03","date_gmt":"2025-07-10T13:08:03","guid":{"rendered":"https:\/\/admarebio.com\/news-events\/news-insights\/"},"modified":"2026-06-26T18:38:25","modified_gmt":"2026-06-26T18:38:25","slug":"epitopea-expands-its-clinical-development-and-research-capabilities-as-it-accelerates-to-the-clinic","status":"publish","type":"post","link":"https:\/\/admarebio.com\/news-events\/news-insights\/epitopea-expands-its-clinical-development-and-research-capabilities-as-it-accelerates-to-the-clinic\/","title":{"rendered":"Epitopea Expands its Clinical Development and Research Capabilities as it Accelerates to the Clinic"},"content":{"rendered":"\n<p><strong>CAMBRIDGE, UK and MONTREAL, CANADA, 10 July 2025<\/strong>&nbsp;\u2013 Epitopea<strong>,<\/strong>&nbsp;a transatlantic cancer immunotherapeutics company developing accessible, off-the-shelf RNA-based immunotherapies, today announced the formation of its dedicated clinical team and<strong>&nbsp;<\/strong>the expansion of its research team<strong>.<\/strong>&nbsp;These developments represent a significant milestone in the company\u2019s ongoing progress in advancing its RNA-based immunotherapies, known as CryptiVax<sup>TM<\/sup>, into clinical trials.&nbsp;&nbsp;<\/p>\n\n\n\n<p>Siri Brinchmann-Hansen Torhaug, Head of Oncology Development, and Gertrud Koefoed Rasmussen, Head of Development Operations, will both join Epitopea\u2019s Executive leadership team. They report into Dr. Klaus Edvardsen, who has served as Epitopea\u2019s Chief Medical Officer (CMO) since February 2025, and oversees the strategic direction of clinical trials and regulatory affairs.&nbsp;<\/p>\n\n\n\n<p>Epitopea\u2019s research team in Cambridge has been extended to include translational immunology capabilities with the appointment of Dr. Theres Oakes as Director of Translational Sciences and Dr. Lisa Smith as Director of Research (UK). Both report into Dr. Jon Moore, Co-founder and Chief Scientific Officer (CSO) of Epitopea, and will work in close collaboration with the clinical team to ensure the seamless integration of research and clinical strategies. &nbsp;<\/p>\n\n\n\n<p>Siri Brinchmann-Hansen Torhaug is a highly accomplished, board-certified, oncology specialist with extensive experience in clinical strategy and development. Siri has worked in various senior leadership roles, including as Chief Medical Officer at Nykode Therapeutics, where she was instrumental in developing clinical strategies for oncology and autoimmune disease therapies. She brings a wealth of experience from working across both early-phase translational research and late-stage clinical trials. At Epitopea, Siri will focus on clinical strategy and development, ensuring that the company\u2019s pipeline moves forward with precision and efficacy.&nbsp;<\/p>\n\n\n\n<p>\u201cIt\u2019s a pleasure to join Epitopea\u2019s Executive and clinical leadership team,\u201d said Siri Brinchmann-Hansen Torhaug, Head of Oncology Development. \u201cWith my background in oncology clinical trials, I am excited to contribute to the company\u2019s innovative work in cancer immunotherapy. I look forward to working alongside Klaus and Gertrud to advance Epitopea\u2019s promising pipeline, with the aim of improving patient outcomes in oncology.\u201d&nbsp;<\/p>\n\n\n\n<p>Gertrud Koefoed Rasmussen brings over 20 years of experience in clinical operations across multiple therapeutic areas, including oncology and rare diseases. Most recently, Gertrud held the position of VP and Head of Development Operations at Nykode Therapeutics, where she built and expanded the clinical operations department and led clinical trials across all phases of development. She has extensive experience in vendor management, regulatory compliance, and process optimization. At Epitopea, Gertrud will lead clinical trial management and regulatory compliance, ensuring that trials are conducted efficiently and in accordance with regulatory guidelines.&nbsp;<\/p>\n\n\n\n<p>\u201cJoining Epitopea is an exciting opportunity to leverage my expertise in clinical operations and contribute to the development of innovative therapies,\u201d said Gertrud Koefoed Rasmussen, Head of Development Operations. \u201cI look forward to collaborating with the team to manage and execute clinical trials that will bring groundbreaking cancer immunotherapies to patients with significant unmet medical needs.\u201d&nbsp;<\/p>\n\n\n\n<p>Dr. Klaus Edvardsen, CMO of Epitopea, commented, \u201cIt is an honor to lead the formation of this clinical team, and I am thrilled to work with Gertrud and Siri, who both bring invaluable experience and expertise to Epitopea. Their leadership will be crucial as we move forward with our clinical trials and work to bring our transformative cancer immunotherapies to the clinic.\u201d&nbsp;<\/p>\n\n\n\n<p>As part of the research team appointments, Dr. Theres Oakes brings extensive expertise in antigen-directed immuno-oncology through her academic training and prior role at Achilles Therapeutics.&nbsp; Dr. Lisa Smith brings considerable experience in drug discovery and oncology from her previous roles at Kudos Therapeutics, Mission Therapeutics and Benevolent AI.&nbsp;<\/p>\n\n\n\n<p>Dr. Jon Moore, CSO and Co-Founder of Epitopea commented, \u201cWe are harnessing the talents of our existing research team and recent joiners to build world-class cancer immunotherapeutics. To this end, we welcome Lisa to accelerate these efforts. Furthermore, with the translational sciences team we are building around Theres, we will have the capability to assess the performance of our immunotherapeutics in patients with unrivalled precision. It has been a real privilege to be able to build such a strong biology group, and I am very excited to see what impact we can make on the treatment of these devastating diseases.\u201d&nbsp;<\/p>\n\n\n\n<p><strong>About Epitopea<\/strong>&nbsp;<br>Epitopea is a transatlantic cancer immunotherapeutics company developing accessible off-the-shelf RNA-based immunotherapies for use in hard-to-treat cancers by targeting a new class of untapped tumor-specific antigens, which are known as Cryptigen<sup>TM<\/sup>\u202fTSAs, that are broadly shared across multiple patients with the same tumor type.\u202f&nbsp;<\/p>\n\n\n\n<p>The company has created an extensive library of novel Cryptigen<sup>TM<\/sup><sup>\u202f<\/sup>TSAs, discovered by its proprietary CryptoMap<sup>TM<\/sup>\u202fplatform that leverages immunopeptidomics, genomics, and a bioinformatics pipeline, allowing the identification of aberrantly-expressed, tumor-specific antigens (aeTSAs) that are hidden within cancer\u2019s \u2019junk\u2019 DNA.\u202f These hidden Cryptigen<sup>TM<\/sup>\u202fTSAs were first discovered through research led by Drs. Claude Perreault and Pierre Thibault at the Institute for Research in Immunology and Cancer at the Universit\u00e9 de Montr\u00e9al.&nbsp;<\/p>\n\n\n\n<p>Epitopea is backed by leading life science investors including Advent Life Sciences, CTI Life Sciences, Cambridge Innovation Capital, Le Fonds de Solidarit\u00e9 FTQ, Investissement Qu\u00e9bec, adMare BioInnovations, Jonathan Milner, the Harrington Discovery Institute, IRICoR and Novateur Ventures. The company has a license and research collaboration with MSD (tradename of Merck &amp; Co., Inc., Rahway, N.J., USA).&nbsp;<\/p>\n\n\n\n<p>Epitopea was founded in 2021 and consists of sister companies based in Cambridge, UK and in Montreal, Canada. For additional information, please visit\u202f<a href=\"http:\/\/www.epitopea.com\/\">www.epitopea.com<\/a>\u202fand follow us on\u202f<a href=\"https:\/\/www.linkedin.com\/company\/epitopea\" rel=\"noreferrer noopener\" target=\"_blank\">LinkedIn<\/a>.<\/p>\n\n\n\n<p><strong>For further information<\/strong>&nbsp;<\/p>\n\n\n\n<p><strong>Epitopea<\/strong>&nbsp;<br>Dr. Alan C. Rigby \u2013 CEO&nbsp;<br><a href=\"mailto:Alan.Rigby@epitopea.com\" rel=\"noreferrer noopener\" target=\"_blank\">Alan.Rigby@epitopea.com<\/a>&nbsp;<\/p>\n\n\n\n<p><strong>Scius Communications\u202f(for Epitopea)<\/strong>&nbsp;<br>Katja Stout&nbsp;<br>+44 7789 435990&nbsp;<br><a href=\"mailto:katja@sciuscommunications.com\" rel=\"noreferrer noopener\" target=\"_blank\">katja@sciuscommunications.com<\/a>&nbsp;<\/p>\n\n\n\n<p>Daniel Gooch&nbsp;<br>+44 7747 875479&nbsp;<br><a href=\"mailto:daniel@sciuscommunications.com\" rel=\"noreferrer noopener\" target=\"_blank\">daniel@sciuscommunications.com<\/a><\/p>\n\n\n\n<p><a href=\"https:\/\/www.epitopea.com\/epitopea-expands-its-clinical-development-and-research-capabilities-as-it-accelerates-to-the-clinic\/\">Read the original press release here<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>CAMBRIDGE, UK and MONTREAL, CANADA, 10 July 2025&nbsp;\u2013 Epitopea,&nbsp;a transatlantic cancer immunotherapeutics company developing accessible, off-the-shelf RNA-based immunotherapies, today announced the formation of its dedicated clinical team and&nbsp;the expansion of [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":1617,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[29],"tags":[],"company":[78],"class_list":["post-1690","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-portfolio-companies"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Epitopea Expands its Clinical Development and Research Capabilities as it Accelerates to the Clinic | adMare<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Epitopea Expands its Clinical Development and Research Capabilities as it Accelerates to the Clinic | adMare\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, UK and MONTREAL, CANADA, 10 July 2025&nbsp;\u2013 Epitopea,&nbsp;a transatlantic cancer immunotherapeutics company developing accessible, off-the-shelf RNA-based immunotherapies, today announced the formation of its dedicated clinical team and&nbsp;the expansion of [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/admarebio.com\/news-events\/news-insights\/epitopea-expands-its-clinical-development-and-research-capabilities-as-it-accelerates-to-the-clinic\/\" \/>\n<meta property=\"og:site_name\" content=\"adMare\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-10T13:08:03+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-26T18:38:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/epitopeanews-en-1739975092.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"628\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Earnscliffe Strategies\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Earnscliffe Strategies\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/epitopea-expands-its-clinical-development-and-research-capabilities-as-it-accelerates-to-the-clinic\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/epitopea-expands-its-clinical-development-and-research-capabilities-as-it-accelerates-to-the-clinic\\\/\"},\"author\":{\"name\":\"Earnscliffe Strategies\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#\\\/schema\\\/person\\\/bd78e975574bdbf66541602c00a312da\"},\"headline\":\"Epitopea Expands its Clinical Development and Research Capabilities as it Accelerates to the Clinic\",\"datePublished\":\"2025-07-10T13:08:03+00:00\",\"dateModified\":\"2026-06-26T18:38:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/epitopea-expands-its-clinical-development-and-research-capabilities-as-it-accelerates-to-the-clinic\\\/\"},\"wordCount\":970,\"publisher\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/epitopea-expands-its-clinical-development-and-research-capabilities-as-it-accelerates-to-the-clinic\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/epitopeanews-en-1739975092.png\",\"articleSection\":[\"Portfolio Companies\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/epitopea-expands-its-clinical-development-and-research-capabilities-as-it-accelerates-to-the-clinic\\\/\",\"url\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/epitopea-expands-its-clinical-development-and-research-capabilities-as-it-accelerates-to-the-clinic\\\/\",\"name\":\"Epitopea Expands its Clinical Development and Research Capabilities as it Accelerates to the Clinic | adMare\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/epitopea-expands-its-clinical-development-and-research-capabilities-as-it-accelerates-to-the-clinic\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/epitopea-expands-its-clinical-development-and-research-capabilities-as-it-accelerates-to-the-clinic\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/epitopeanews-en-1739975092.png\",\"datePublished\":\"2025-07-10T13:08:03+00:00\",\"dateModified\":\"2026-06-26T18:38:25+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/epitopea-expands-its-clinical-development-and-research-capabilities-as-it-accelerates-to-the-clinic\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/epitopea-expands-its-clinical-development-and-research-capabilities-as-it-accelerates-to-the-clinic\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/epitopea-expands-its-clinical-development-and-research-capabilities-as-it-accelerates-to-the-clinic\\\/#primaryimage\",\"url\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/epitopeanews-en-1739975092.png\",\"contentUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/epitopeanews-en-1739975092.png\",\"width\":1200,\"height\":628},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/epitopea-expands-its-clinical-development-and-research-capabilities-as-it-accelerates-to-the-clinic\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/admarebio.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News &#038; Events\",\"item\":\"https:\\\/\\\/admarebio.com\\\/en\\\/news-events\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"News &#038; Insights\",\"item\":\"https:\\\/\\\/admarebio.com\\\/en\\\/news-events\\\/news-insights\\\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Epitopea Expands its Clinical Development and Research Capabilities as it Accelerates to the Clinic\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/admarebio.com\\\/en\\\/\",\"name\":\"adMare\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/admarebio.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#organization\",\"name\":\"adMare\",\"url\":\"https:\\\/\\\/admarebio.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/Logo-light.svg\",\"contentUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/Logo-light.svg\",\"width\":915,\"height\":337,\"caption\":\"adMare\"},\"image\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#\\\/schema\\\/person\\\/bd78e975574bdbf66541602c00a312da\",\"name\":\"Earnscliffe Strategies\",\"url\":\"#\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Epitopea Expands its Clinical Development and Research Capabilities as it Accelerates to the Clinic | adMare","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"Epitopea Expands its Clinical Development and Research Capabilities as it Accelerates to the Clinic | adMare","og_description":"CAMBRIDGE, UK and MONTREAL, CANADA, 10 July 2025&nbsp;\u2013 Epitopea,&nbsp;a transatlantic cancer immunotherapeutics company developing accessible, off-the-shelf RNA-based immunotherapies, today announced the formation of its dedicated clinical team and&nbsp;the expansion of [&hellip;]","og_url":"https:\/\/admarebio.com\/news-events\/news-insights\/epitopea-expands-its-clinical-development-and-research-capabilities-as-it-accelerates-to-the-clinic\/","og_site_name":"adMare","article_published_time":"2025-07-10T13:08:03+00:00","article_modified_time":"2026-06-26T18:38:25+00:00","og_image":[{"width":1200,"height":628,"url":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/epitopeanews-en-1739975092.png","type":"image\/png"}],"author":"Earnscliffe Strategies","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Earnscliffe Strategies","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/admarebio.com\/news-events\/news-insights\/epitopea-expands-its-clinical-development-and-research-capabilities-as-it-accelerates-to-the-clinic\/#article","isPartOf":{"@id":"https:\/\/admarebio.com\/news-events\/news-insights\/epitopea-expands-its-clinical-development-and-research-capabilities-as-it-accelerates-to-the-clinic\/"},"author":{"name":"Earnscliffe Strategies","@id":"https:\/\/admarebio.com\/en\/#\/schema\/person\/bd78e975574bdbf66541602c00a312da"},"headline":"Epitopea Expands its Clinical Development and Research Capabilities as it Accelerates to the Clinic","datePublished":"2025-07-10T13:08:03+00:00","dateModified":"2026-06-26T18:38:25+00:00","mainEntityOfPage":{"@id":"https:\/\/admarebio.com\/news-events\/news-insights\/epitopea-expands-its-clinical-development-and-research-capabilities-as-it-accelerates-to-the-clinic\/"},"wordCount":970,"publisher":{"@id":"https:\/\/admarebio.com\/en\/#organization"},"image":{"@id":"https:\/\/admarebio.com\/news-events\/news-insights\/epitopea-expands-its-clinical-development-and-research-capabilities-as-it-accelerates-to-the-clinic\/#primaryimage"},"thumbnailUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/epitopeanews-en-1739975092.png","articleSection":["Portfolio Companies"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/admarebio.com\/news-events\/news-insights\/epitopea-expands-its-clinical-development-and-research-capabilities-as-it-accelerates-to-the-clinic\/","url":"https:\/\/admarebio.com\/news-events\/news-insights\/epitopea-expands-its-clinical-development-and-research-capabilities-as-it-accelerates-to-the-clinic\/","name":"Epitopea Expands its Clinical Development and Research Capabilities as it Accelerates to the Clinic | adMare","isPartOf":{"@id":"https:\/\/admarebio.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/admarebio.com\/news-events\/news-insights\/epitopea-expands-its-clinical-development-and-research-capabilities-as-it-accelerates-to-the-clinic\/#primaryimage"},"image":{"@id":"https:\/\/admarebio.com\/news-events\/news-insights\/epitopea-expands-its-clinical-development-and-research-capabilities-as-it-accelerates-to-the-clinic\/#primaryimage"},"thumbnailUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/epitopeanews-en-1739975092.png","datePublished":"2025-07-10T13:08:03+00:00","dateModified":"2026-06-26T18:38:25+00:00","breadcrumb":{"@id":"https:\/\/admarebio.com\/news-events\/news-insights\/epitopea-expands-its-clinical-development-and-research-capabilities-as-it-accelerates-to-the-clinic\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/admarebio.com\/news-events\/news-insights\/epitopea-expands-its-clinical-development-and-research-capabilities-as-it-accelerates-to-the-clinic\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/admarebio.com\/news-events\/news-insights\/epitopea-expands-its-clinical-development-and-research-capabilities-as-it-accelerates-to-the-clinic\/#primaryimage","url":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/epitopeanews-en-1739975092.png","contentUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/epitopeanews-en-1739975092.png","width":1200,"height":628},{"@type":"BreadcrumbList","@id":"https:\/\/admarebio.com\/news-events\/news-insights\/epitopea-expands-its-clinical-development-and-research-capabilities-as-it-accelerates-to-the-clinic\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/admarebio.com\/en\/"},{"@type":"ListItem","position":2,"name":"News &#038; Events","item":"https:\/\/admarebio.com\/en\/news-events\/"},{"@type":"ListItem","position":3,"name":"News &#038; Insights","item":"https:\/\/admarebio.com\/en\/news-events\/news-insights\/"},{"@type":"ListItem","position":4,"name":"Epitopea Expands its Clinical Development and Research Capabilities as it Accelerates to the Clinic"}]},{"@type":"WebSite","@id":"https:\/\/admarebio.com\/en\/#website","url":"https:\/\/admarebio.com\/en\/","name":"adMare","description":"","publisher":{"@id":"https:\/\/admarebio.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/admarebio.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/admarebio.com\/en\/#organization","name":"adMare","url":"https:\/\/admarebio.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/admarebio.com\/en\/#\/schema\/logo\/image\/","url":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/03\/Logo-light.svg","contentUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/03\/Logo-light.svg","width":915,"height":337,"caption":"adMare"},"image":{"@id":"https:\/\/admarebio.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/admarebio.com\/en\/#\/schema\/person\/bd78e975574bdbf66541602c00a312da","name":"Earnscliffe Strategies","url":"#"}]}},"_links":{"self":[{"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/posts\/1690","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/comments?post=1690"}],"version-history":[{"count":1,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/posts\/1690\/revisions"}],"predecessor-version":[{"id":1691,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/posts\/1690\/revisions\/1691"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/media\/1617"}],"wp:attachment":[{"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/media?parent=1690"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/categories?post=1690"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/tags?post=1690"},{"taxonomy":"company","embeddable":true,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/company?post=1690"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}